Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer.

This synergistic interaction was even more evident in the 4041 model, whose tumors were completely refractory to ABT-263/navitoclax and ABT-199/venetoclax monotherapy, but achieved highly significant tumor responses –up to 71 % TGI rates– when combined with TVB-3664 ( Fig. 5 ).

also in 132,142 other papers